FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984845830> ?p ?o ?g. }

• W2984845830 endingPage "2900" @default.
• W2984845830 startingPage "2900" @default.
• W2984845830 abstract "Introduction Central nervous system lymphoma (CNSL) is a rare neoplasia and arises as primary (PCNSL) or secondary CNSL (SCNSL) and most commonly occurs as diffuse large B-cell lymphoma. Although prognosis of this disease has significantly improved due to advantages in diagnostic procedures and intensification of treatment over the last decade there remain major challenges in the clinical management. Magnetic resonance imaging (MRI) - as the standard imaging modality - has difficulties to discriminate CNSL from other brain-derived tumors or metastasis. Moreover, prognostic scores in CNSL lack the ability to reliable define patients with high relapse risk 1. Therefore, novel strategies to facilitate diagnosis and to select patients that profit from intense treatment protocols are urgently needed. The C-X-C chemokine receptor 4 (CXCR4) is a transmembrane chemokine receptor with pivotal roles in cell homing and is often overexpressed in hematologic malignancies. CXCR4-directed positron emission tomography (PET) imaging with the tracer [68Ga]Pentixafor has been proven to be a suitable in vivo imaging modality for CXCR4 expression in lymphoid malignancies 2. To evaluate the feasibility of CXCR4-directed PET and the prognostic value of this imaging modality this retrospective proof-of-concept study evaluated [68Ga]Pentixafor PET imaging in patients with CNSL. Methods 11 patients with lymphoma of the CNS (n=8 PCNSL, n=3 SCNSL) were imaged with the CXCR4-directed PET tracer [68Ga]Pentixafor in this retrospective proof-of-concept study after signing inform consent. Lymphoma tissue was assessed for CXCR4 expression ex vivo by immunohistochemistry. The prognostic value of CXCR4-directed PET imaging was evaluated in a computed analysis in 7 patients with follow-up MRI. Treatment response calculated as treatment efficiency η by sequential MRI was correlated with [68Ga]Pentixafor PET derived parameters at diagnosis such as volume of PET positive lymphoma lesion V(PET), maximal PET uptake value within the lesion max(PET) or integrated uptake values over the lymphoma lesion ∫(PET). Analysis was performed in a lesion- and patient-based manner. Results [68Ga]Pentixafor PET imaging was positive in all patients with active disease (10/11 patients) with excellent contrast characteristics to the surrounding brain parenchyma. PET positive lesions correlated well with lymphoma lesions in MRI-T1c sequences. The surrounding edema depicted in MRI-FLAIR sequences was evaluated as PET negative (Figure 1). Semi-quantitative analysis revealed maximum standard uptake values of [68Ga]Pentixafor-derived PET from 4.2 to 23.3 within the lesions with a high tumor-to-background-ratio ranging from 13.2 to 83.0. The computed analysis revealed that CXCR4-directed PET parameters at diagnosis given by max(PET) and ∫(PET) significantly correlated with treatment response in the lesion-based as well as in the patient-based analysis. Specifically, ∫(PET) was the most significant prognostic factor in the present study (Figure 2 C, D, F). On the other hand tumor volume at diagnosis measured either by MRI or by [68Ga]Pentixafor PET did not denote a predictive marker for treatment response (Figure 2 A, B, E). Conclusion/Outlook CXCR4-directed PET imaging represents a novel imaging modality for CNSL. Due to its excellent contrast properties it might help to facilitate diagnosis and refine response assessment. Moreover, owing the predictive value for treatment response, CXCR4-directed PET could serve as a biomarker for the selection of patients profiting from intense treatment protocols. Furthermore, the feasibility of endoradiotherapeutic approaches targeting CXCR4 with Pentixather - the therapeutic twin of the imaging peptide Pentixafor - has been shown in hematologic malignancies and could be incorporated in the treatment of CNSL. References 1. Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer. 2017;123(22):4314-4324. 2.Kircher M, Herhaus P, Schottelius M, et al. CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med. 2018;32(8):503-511. Disclosures Wester: Scintomics: Other: Spouse CEO of Company; CXCR4-targeted radiopharmaceuticals: Other: Inventor; Scintomics GmbH, Germany: Other: Shareholder. Bassermann:Celgene: Consultancy, Research Funding." @default.
• W2984845830 created "2019-11-22" @default.
• W2984845830 creator A5000481071 @default.
• W2984845830 creator A5003690611 @default.
• W2984845830 creator A5011532208 @default.
• W2984845830 creator A5019652919 @default.
• W2984845830 creator A5021273661 @default.
• W2984845830 creator A5028510513 @default.
• W2984845830 creator A5030332648 @default.
• W2984845830 creator A5030849064 @default.
• W2984845830 creator A5048659792 @default.
• W2984845830 creator A5049197829 @default.
• W2984845830 creator A5051959238 @default.
• W2984845830 creator A5059538708 @default.
• W2984845830 creator A5062182791 @default.
• W2984845830 creator A5069685916 @default.
• W2984845830 creator A5073895168 @default.
• W2984845830 creator A5076736029 @default.
• W2984845830 creator A5080877411 @default.
• W2984845830 creator A5082924805 @default.
• W2984845830 creator A5088874257 @default.
• W2984845830 date "2019-11-13" @default.
• W2984845830 modified "2023-10-01" @default.
• W2984845830 title "CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma" @default.
• W2984845830 doi "https://doi.org/10.1182/blood-2019-126024" @default.
• W2984845830 hasPublicationYear "2019" @default.
• W2984845830 type Work @default.
• W2984845830 sameAs 2984845830 @default.
• W2984845830 citedByCount "1" @default.
• W2984845830 countsByYear W29848458302021 @default.
• W2984845830 crossrefType "journal-article" @default.
• W2984845830 hasAuthorship W2984845830A5000481071 @default.
• W2984845830 hasAuthorship W2984845830A5003690611 @default.
• W2984845830 hasAuthorship W2984845830A5011532208 @default.
• W2984845830 hasAuthorship W2984845830A5019652919 @default.
• W2984845830 hasAuthorship W2984845830A5021273661 @default.
• W2984845830 hasAuthorship W2984845830A5028510513 @default.
• W2984845830 hasAuthorship W2984845830A5030332648 @default.
• W2984845830 hasAuthorship W2984845830A5030849064 @default.
• W2984845830 hasAuthorship W2984845830A5048659792 @default.
• W2984845830 hasAuthorship W2984845830A5049197829 @default.
• W2984845830 hasAuthorship W2984845830A5051959238 @default.
• W2984845830 hasAuthorship W2984845830A5059538708 @default.
• W2984845830 hasAuthorship W2984845830A5062182791 @default.
• W2984845830 hasAuthorship W2984845830A5069685916 @default.
• W2984845830 hasAuthorship W2984845830A5073895168 @default.
• W2984845830 hasAuthorship W2984845830A5076736029 @default.
• W2984845830 hasAuthorship W2984845830A5080877411 @default.
• W2984845830 hasAuthorship W2984845830A5082924805 @default.
• W2984845830 hasAuthorship W2984845830A5088874257 @default.
• W2984845830 hasBestOaLocation W29848458301 @default.
• W2984845830 hasConcept C126322002 @default.
• W2984845830 hasConcept C126838900 @default.
• W2984845830 hasConcept C12823836 @default.
• W2984845830 hasConcept C129470790 @default.
• W2984845830 hasConcept C13373296 @default.
• W2984845830 hasConcept C142724271 @default.
• W2984845830 hasConcept C143409427 @default.
• W2984845830 hasConcept C170493617 @default.
• W2984845830 hasConcept C2775842073 @default.
• W2984845830 hasConcept C2779338263 @default.
• W2984845830 hasConcept C2781173314 @default.
• W2984845830 hasConcept C71924100 @default.
• W2984845830 hasConceptScore W2984845830C126322002 @default.
• W2984845830 hasConceptScore W2984845830C126838900 @default.
• W2984845830 hasConceptScore W2984845830C12823836 @default.
• W2984845830 hasConceptScore W2984845830C129470790 @default.
• W2984845830 hasConceptScore W2984845830C13373296 @default.
• W2984845830 hasConceptScore W2984845830C142724271 @default.
• W2984845830 hasConceptScore W2984845830C143409427 @default.
• W2984845830 hasConceptScore W2984845830C170493617 @default.
• W2984845830 hasConceptScore W2984845830C2775842073 @default.
• W2984845830 hasConceptScore W2984845830C2779338263 @default.
• W2984845830 hasConceptScore W2984845830C2781173314 @default.
• W2984845830 hasConceptScore W2984845830C71924100 @default.
• W2984845830 hasIssue "Supplement_1" @default.
• W2984845830 hasLocation W29848458301 @default.
• W2984845830 hasOpenAccess W2984845830 @default.
• W2984845830 hasPrimaryLocation W29848458301 @default.
• W2984845830 hasRelatedWork W1964188692 @default.
• W2984845830 hasRelatedWork W2338711541 @default.
• W2984845830 hasRelatedWork W2355796160 @default.
• W2984845830 hasRelatedWork W2381735876 @default.
• W2984845830 hasRelatedWork W2495617462 @default.
• W2984845830 hasRelatedWork W2805966349 @default.
• W2984845830 hasRelatedWork W2945153831 @default.
• W2984845830 hasRelatedWork W2984845830 @default.
• W2984845830 hasRelatedWork W2990451859 @default.
• W2984845830 hasRelatedWork W4245701383 @default.
• W2984845830 hasVolume "134" @default.
• W2984845830 isParatext "false" @default.
• W2984845830 isRetracted "false" @default.
• W2984845830 magId "2984845830" @default.
• W2984845830 workType "article" @default.